Weak Statutory Earnings May Not Tell The Whole Story For Shandong Weigao Orthopaedic Device (SHSE:688161)
Weak Statutory Earnings May Not Tell The Whole Story For Shandong Weigao Orthopaedic Device (SHSE:688161)
Despite Shandong Weigao Orthopaedic Device Co., Ltd's (SHSE:688161) recent earnings report having lackluster headline numbers, the market responded positively. While shareholders may be willing to overlook soft profit numbers, we believe that they should also be taking into account some other factors which may be cause for concern.
尽管山东微致骨科医疗器械有限公司(SHSE:688161)最近的收益报告头条数字不尽如人意,但市场的反应却是积极的。 虽然股东们可能愿意忽略利润数字偏弱,但我们认为他们也应该考虑到一些其他可能引起关注的因素。
How Do Unusual Items Influence Profit?
非常规项目如何影响利润?
For anyone who wants to understand Shandong Weigao Orthopaedic Device's profit beyond the statutory numbers, it's important to note that during the last twelve months statutory profit gained from CN¥29m worth of unusual items. While we like to see profit increases, we tend to be a little more cautious when unusual items have made a big contribution. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. And, after all, that's exactly what the accounting terminology implies. Shandong Weigao Orthopaedic Device had a rather significant contribution from unusual items relative to its profit to September 2024. As a result, we can surmise that the unusual items are making its statutory profit significantly stronger than it would otherwise be.
对于想要了解山东微致骨科医疗器械公司超出法定数字的利润的人,重要的是要注意,在过去十二个月中,法定利润增长了约2900万人民币的飞凡项目。 虽然我们乐见利润增长,但当飞凡项目做出重大贡献时,我们往往会更加谨慎。 在分析了全球绝大多数上市公司后,我们发现重大的飞凡项目往往不会重复。 而且,毕竟,这正是会计术语所暗示的。 2024年9月,山东微致骨科医疗器械公司由于飞凡项目相对于其利润的显着贡献,使其法定利润相比于以往更强。 因此,我们可以推断出这些飞凡项目使其法定利润显著强于否则可能的情况。
That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.
这可能会让您想知道分析师对未来盈利能力的预测。幸运的是,您可以单击此处查看基于其估计的未来盈利能力的互动图表。
Our Take On Shandong Weigao Orthopaedic Device's Profit Performance
我们对山东微致骨科医疗器械公司的利润表现的看法
As we discussed above, we think the significant positive unusual item makes Shandong Weigao Orthopaedic Device's earnings a poor guide to its underlying profitability. As a result, we think it may well be the case that Shandong Weigao Orthopaedic Device's underlying earnings power is lower than its statutory profit. In further bad news, its earnings per share decreased in the last year. At the end of the day, it's essential to consider more than just the factors above, if you want to understand the company properly. Obviously, we love to consider the historical data to inform our opinion of a company. But it can be really valuable to consider what other analysts are forecasting. At Simply Wall St, we have analyst estimates which you can view by clicking here.
正如我们上面所讨论的,我们认为重要的正常外来因素使得山东威高骨科器械的收益成为其潜在盈利能力的不佳指导。因此,我们认为山东威高骨科器械的潜在盈利能力很可能低于其法定利润。在进一步的坏消息中,其每股收益在过去一年中有所下降。归根结底,要更全面地了解公司,不仅需要考虑以上因素。显然,我们乐于考虑历史数据来帮助我们对一家公司的看法。但考虑其他分析师的预测可能非常有价值。 在Simply Wall St,我们有分析师的预估数据,您可以通过点击这里查看。
This note has only looked at a single factor that sheds light on the nature of Shandong Weigao Orthopaedic Device's profit. But there are plenty of other ways to inform your opinion of a company. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks with high insider ownership.
本注只讨论了一个可以揭示山东威高骨科器械利润性质的单一因素。但还有很多其他方式可以帮助您了解一家公司。例如,许多人将高股本回报视为有利可图的商业经济指标,而其他人则喜欢“跟着钱走”,寻找内部人员正在买入的股票。因此,您可能希望查看这份免费的公司收藏,其中包括具有高股本回报率的公司,或者这份拥有高内部所有权的股票清单。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对本文有任何反馈?对内容有任何疑虑?请直接与我们联系。或者,发送电子邮件至editorial-team@simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。